Acorda Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Acorda Therapeutics, Inc. - overview
Established
1995
Location
-, NY, US
Primary Industry
Pharmaceuticals
About
Acorda Therapeutics, Inc. focuses on developing and commercializing innovative therapies aimed at improving the quality of life for patients with neurological diseases. Acorda Therapeutics, Inc. specializes in therapies for neurological disorders.
Founded in 1995 in the U. S. , the company has undergone various strategic developments over the years. The current CEO is Ron Cohen.
Acorda's significant milestone includes raising USD 31. 50 mn through a PIPE funding round, which represents the total amount raised by the firm. The most recent deal occurred on February 1, 2011, following a previous listing that raised USD 33 mn in 2006. Acorda Therapeutics Inc.
specializes in developing and commercializing innovative therapies for neurological diseases. Their core offerings include AMPYRA® (dalfampridine), a treatment designed to improve walking in patients with multiple sclerosis, and INBRIJA® (levodopa inhalation powder), utilized for managing off periods in patients with Parkinson's disease. These products aim to alleviate symptoms and enhance the quality of life for individuals facing challenges from these neurological conditions. Additionally, Acorda has developed ARCUS® technology, facilitating effective medication delivery and primarily markets its products in North America and select European regions.
Acorda Therapeutics generated revenue of USD 117. 63 mn in 2023. The company's revenue is driven by the sale of its pharmaceutical products, particularly AMPYRA® and INBRIJA®. Transactions typically involve wholesalers purchasing the products at wholesale prices, which are subsequently sold to healthcare providers and pharmacies, ensuring access for end users.
The pricing strategy reflects the innovative nature and clinical benefits of these therapies, maintaining a viable economic model for the business. Acorda Therapeutics plans to leverage recent funding to support the development of new products and expand into new geographic markets. The company is focusing on upcoming therapies and is targeting regions that include Europe and specific markets in North America. The funding raised in the PIPE round will be utilized to advance their product pipeline and support market-entry strategies, following a notable deal in February 2006 where they raised USD 33 mn.
Current Investors
Paul Capital, Forward Ventures, RBC Capital Markets
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Epidemiology, Pharmaceutical Research & Development
Website
www.acorda.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Acorda Therapeutics, Inc. - timeline of key events
Acorda Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 292,237,000 | 305,814,000 | 336,430,000 | 401,480,000 | 492,660,000 | 519,601,000 | 588,287,000 | 471,433,000 | 192,408,000 | 152,967,000 | - | - | - |
| % Revenue Growth (YoY) | - | 4.6% | 10.0% | 19.3% | 22.7% | 5.5% | 13.2% | (19.9%) | (59.2%) | (20.5%) | - | - | - |
| EBITDA (USD) | 46,533,000 | 34,714,000 | 39,940,000 | 52,753,000 | 60,945,000 | (4,216,000) | (197,427,000) | 64,370,000 | (262,982,000) | (19,794,000) | - | - | - |
| Operating Income (USD) | 35,054,000 | 25,602,000 | 30,365,000 | 36,391,000 | 33,990,000 | (35,982,000) | (232,814,000) | 38,486,000 | (311,632,000) | (78,076,000) | - | - | - |
| Operating Margin | 12.0% | 8.4% | 9.0% | 9.1% | 6.9% | (6.9%) | (39.6%) | 8.2% | (162.0%) | (51.0%) | - | - | - |
| % EBITDA Margin | 15.9% | 11.4% | 11.9% | 13.1% | 12.4% | (0.8%) | (33.6%) | 13.7% | (136.7%) | (12.9%) | - | - | - |
| NET Income (USD) | 30,605,000 | 154,958,000 | 16,441,000 | 17,672,000 | 11,058,000 | (35,603,000) | (223,359,000) | 33,682,000 | (272,966,000) | (99,594,000) | - | - | - |
| % Net Margin | 10.5% | 50.7% | 4.9% | 4.4% | 2.2% | (6.9%) | (38.0%) | 7.1% | (141.9%) | (65.1%) | - | - | - |
Acorda Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.